Related references
Note: Only part of the references are listed.Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor
Veronica H. Flood et al.
BLOOD (2010)
Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD
V. H. Flood et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor
Anne F. Riddell et al.
BLOOD (2009)
von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)
W. L. Nichols et al.
HAEMOPHILIA (2008)
An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult
Emmanuel J. Favaloro
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2007)
Assessing bleeding in von Willebrand disease with bleeding score
Alberto Tosetto et al.
BLOOD REVIEWS (2007)
Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)
Anne Goodeve et al.
BLOOD (2007)
Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival
Sandra L. Haberichter et al.
BLOOD (2006)
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor
J. E. Sadler et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)
A Tosetto et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Drug therapy - Treatment of von Willebrand's disease
PM Mannucci
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
